Display options
Cite
Heal C, Ding W, Lamond J, et al. Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting. Front Oncol. 2015;5:146doi: 10.3389/fonc.2015.00146.
Heal, C., Ding, W., Lamond, J., Wong, M., Lanciano, R., Su, S., Yang, J., Feng, J., Arrigo, S., Markiewicz, D., Hanlon, A., & Brady, L. (2015). Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting. Frontiers in oncology, 5146. https://doi.org/10.3389/fonc.2015.00146
Heal, Cory, et al. "Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting." Frontiers in oncology vol. 5 (2015): 146. doi: https://doi.org/10.3389/fonc.2015.00146
Heal C, Ding W, Lamond J, Wong M, Lanciano R, Su S, Yang J, Feng J, Arrigo S, Markiewicz D, Hanlon A, Brady L. Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting. Front Oncol. 2015 Jun 30;5:146. doi: 10.3389/fonc.2015.00146. eCollection 2015. PMID: 26175966; PMCID: PMC4485161.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2015 Jun 30;5:146. doi: 10.3389/fonc.2015.00146. eCollection 2015.

Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting.

Frontiers in oncology

Cory Heal, William Ding, John Lamond, Michael Wong, Rachelle Lanciano, Stacy Su, Jun Yang, Jing Feng, Stephen Arrigo, Deborah Markiewicz, Alexandra Hanlon, Luther Brady

Affiliations

  1. Drexel University College of Medicine , Philadelphia, PA , USA.
  2. Drexel University College of Medicine , Philadelphia, PA , USA ; Philadelphia CyberKnife , Philadelphia, PA , USA ; Crozer Keystone Healthcare System , Philadelphia, PA , USA.
  3. David Geffen School of Medicine at UCLA , Los Angeles, CA , USA.
  4. Fox Chase Cancer Center , Philadelphia, PA , USA.
  5. Philadelphia CyberKnife , Philadelphia, PA , USA ; Crozer Keystone Healthcare System , Philadelphia, PA , USA.
  6. Drexel University College of Medicine , Philadelphia, PA , USA ; Philadelphia CyberKnife , Philadelphia, PA , USA.
  7. University of Pennsylvania , Philadelphia, PA , USA.

PMID: 26175966 PMCID: PMC4485161 DOI: 10.3389/fonc.2015.00146

Abstract

INTRODUCTION: Stereotactic ablative body radiotherapy (SABR) provides a superior non-small cell lung cancer (NSCLC) treatment option when compared to conventional radiotherapy for patients deemed inoperable or refusing surgery. This study retrospectively analyzed the rates of tumor control and toxicity following SABR treatment (Cyberknife system) of primary early-stage NSCLC in a community setting.

METHODS: One hundred patients were treated between 2007 and 2011. Patients with T3-4 or N1-3 disease, metastasis, recurrent local disease, or a non-lung primary were excluded from analysis. All patients had biopsy proven disease. Staging included CT or fluorodeoxyglucose-positron emission tomography scan. Median dose was 54 Gy (45-60); 18 Gy (10-20) per fraction. Median planned target volume expansion was 8 mm (2-10). Median BED was 151.2. Tumors were tracked via Synchrony, X-Sight Lung, or X-Sight Spine. Patients were evaluated for local control, overall survival (OS), and toxicity. All local failures were determined by evaluating post treatment PET/CT.

RESULTS: With a median follow up of 27.5 months, the 1-, 2-, and 3-year local control rates were 100, 93.55, and 84.33%, respectively. Median survival was 2.29 years; actuarial 3-year survival was 37.20%. Grade-3 toxicity was observed in 2% of patients (pneumonia within 2 months of treatment, n = 1; chronic pneumonitis requiring hospital admission, n = 1). No patients demonstrated toxicity above Grade-3. Multivariate analysis did not show T-stage as an independent predictor of OS, though it did trend toward significance.

CONCLUSION: In a community-center setting, definitive treatment of NSCLC with SABR for non-surgical candidates and those who choose to forego surgery result in excellent and comparable rates of local control and toxicity compared to published series from large academic centers.

Keywords: XSight; cyberknife; early-stage lung cancer; non-small cell lung cancer; radiation oncology; radiation toxicity; stereotactic ablative radiotherapy; stereotactic body radiotherapy

References

  1. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1010-5 - PubMed
  2. Chest. 2003 Nov;124(5):1946-55 - PubMed
  3. JAMA. 2010 Mar 17;303(11):1070-6 - PubMed
  4. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1427-31 - PubMed
  5. J Thorac Oncol. 2012 Sep;7(9):1382-93 - PubMed
  6. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e305-16 - PubMed
  7. J Thorac Oncol. 2012 Sep;7(9):1394-9 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):344-50 - PubMed
  9. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):374-81 - PubMed
  10. Cancer. 2011 Oct 1;117(19):4566-72 - PubMed
  11. Cancer. 2004 Oct 1;101(7):1623-31 - PubMed
  12. Clin Cancer Res. 2008 Aug 15;14(16):5013-21 - PubMed
  13. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):348-53 - PubMed
  14. Cell. 2014 Aug 28;158(5):1110-22 - PubMed
  15. J Clin Oncol. 2006 Oct 20;24(30):4833-9 - PubMed
  16. J Thorac Oncol. 2013 Aug;8(8):1050-8 - PubMed
  17. Clin Cancer Res. 2009 Nov 15;15(22):6980-6 - PubMed
  18. J Thorac Oncol. 2011 Dec;6(12):2036-43 - PubMed
  19. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e299-303 - PubMed
  20. J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100 - PubMed
  21. Acta Oncol. 2006;45(7):787-95 - PubMed
  22. Chest. 2006 Sep;130(3):710-8 - PubMed
  23. Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):277-84 - PubMed

Publication Types